MG
IDXX icon

Michael Gelband’s Idexx Laboratories IDXX Stock Holding History

Michael Gelband’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$1.26M – 2353
2021
Q2 		$1.26M Buy
+2,000
New +$1.1M 0.01% 883

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Michael Gelband's IDXX Position: Q2 2026 in Review

Michael Gelband opened a new position in Idexx Laboratories (IDXX) in Q2 2026: 12,971 shares worth $6.83M. The stake represents 0.04% of the portfolio and ranks #398 among its holdings. This is a return to the name: Michael Gelband previously reported a position in IDXX as recently as Q4 2025.

Michael Gelband first reported a position in IDXX in Q4 2018 and has held it in 16 quarters since. The position peaked at $23.1M in Q4 2024. 1,293 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Michael Gelband held 12,971 shares of Idexx Laboratories worth $6.83M as of Q2 2026.
  • Idexx Laboratories was a new Michael Gelband position in Q2 2026.
  • Idexx Laboratories made up 0.04% of Michael Gelband's portfolio in Q2 2026, its #398 holding.
  • Michael Gelband first reported a position in Idexx Laboratories in Q4 2018 and has held it in 16 quarters since.
  • Michael Gelband's Idexx Laboratories position peaked at $23.1M in Q4 2024.
  • 1,293 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.